St. James's Hospital, Multidisciplinary Intensive Care Research Organization (MICRO), Trinity Centre for Health Sciences, Dublin, Ireland; Critical Care Center, Corporacion Sanitaria Parc Taulí, CIBER Enfermedades Respiratorias, Parc Tauli, University Institute, Sabadell, Spain.
Hospital Clinic, IDIBAPS, Universitat de Barcelona, CIBER Enfermedades Respiratorias, Servei de Pneumologia, Institut del Torax, Barcelona, Spain.
J Infect. 2015 Mar;70(3):213-22. doi: 10.1016/j.jinf.2014.10.004. Epub 2014 Oct 27.
Bacterial resistance has become a major public health problem.
To validate the definition of multidrug-resistant organisms (MDRO) based on the European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification.
Prospective, observational study in six medical and surgical Intensive-Care-Units (ICU) of a University hospital.
Three-hundred-and-forty-three patients with ICU-acquired pneumonia (ICUAP) were prospectively enrolled, 140 patients had no microbiological confirmation (41%), 82 patients (24%) developed ICUAP for non-MDRO, whereas 121 (35%) were MDROs. Non-MDRO, MDRO and no microbiological confirmation patients did not present either a significant different previous antibiotic use (p 0.18) or previous hospital admission (p 0.17). Appropriate antibiotic therapy was associated with better ICU survival (105 [92.9%] vs. 74 [82.2%]; p = 0.03). An adjusted multivariate regression logistic analysis identified that only MDRO had a higher ICU-mortality than non-MDRO and no microbiological confirmation patients (OR 2.89; p < 0.05; 95% CI for Exp [β]. 1.02-8.21); Patients with MDRO ICUAP remained in ICU for a longer period than MDRO and no microbiological confirmation respectively (p < 0.01) however no microbiological confirmation patients had more often antibiotic consumption than culture positive ones.
Patients who developed ICUAP due to MDRO showed a higher ICU-mortality than non-MDRO ones and use of ICU resources. No microbiological confirmation patients had more often antibiotic consumption than culture positive patients. Risk factors for MDRO may be important for the selection of initial antimicrobial therapy, in addition to local epidemiology.
细菌耐药性已成为一个主要的公共卫生问题。
验证基于欧洲疾病预防控制中心(ECDC)和疾病控制与预防中心(CDC)分类的多药耐药菌(MDRO)定义。
在一家大学医院的六个内科和外科重症监护病房(ICU)进行前瞻性、观察性研究。
前瞻性纳入 343 例 ICU 获得性肺炎(ICUAP)患者,140 例无微生物学证实(41%),82 例(24%)为非 MDRO ICUAP,121 例(35%)为 MDRO。非 MDRO、MDRO 和无微生物学证实的患者在前抗生素使用(p 0.18)或前住院(p 0.17)方面没有显著差异。适当的抗生素治疗与 ICU 存活率的提高相关(105 [92.9%] vs. 74 [82.2%];p = 0.03)。多变量调整逻辑回归分析确定,只有 MDRO 的 ICU 死亡率高于非 MDRO 和无微生物学证实的患者(OR 2.89;p < 0.05;95%CI 为 Exp [β]。1.02-8.21);MDRO ICUAP 患者在 ICU 的停留时间长于 MDRO 和无微生物学证实的患者(p < 0.01),但无微生物学证实的患者比培养阳性的患者抗生素使用更多。
因 MDRO 而发生 ICUAP 的患者 ICU 死亡率和 ICU 资源利用率高于非 MDRO 患者。无微生物学证实的患者比培养阳性的患者抗生素使用更多。MDRO 的危险因素可能对初始抗菌治疗的选择很重要,此外还需要考虑当地的流行病学情况。